参考文献:
[1] Moonshi S S, Adelnia H, Wu Y, et al. Placenta‐Derived Mesenchymal Stem Cells for Treatment of Diseases: A Clinically Relevant Source[J]. Advanced Therapeutics, 2022, 5(10): 2200054.
链接:https://onlinelibrary.wiley.com/doi/full/10.1002/adtp.202200054
[2] Yang Y, Pang M, Du C, et al. Repeated subarachnoid administrations of allogeneic human umbilical cord mesenchymal stem cells for spinal cord injury: a phase 1/2 pilot study[J]. Cytotherapy, 2021, 23(1): 57-64.
链接:https://pubmed.ncbi.nlm.nih.gov/33218835/
[3] Özmert E, Arslan U. Management of retinitis pigmentosa by Wharton’s jelly-derived mesenchymal stem cells: prospective analysis of 1-year results[J]. Stem Cell Research & Therapy, 2020, 11: 353.
链接:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425139/
[4] Cao Y, Sun H, Zhu H, et al. Allogeneic cell therapy using umbilical cord MSCs on collagen scaffolds for patients with recurrent uterine adhesion: a phase I clinical trial[J]. Stem Cell Research & Therapy, 2018, 9: 192.
链接:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6042450/
[5] Wang D, Niu L, Feng X, Yuan X, Zhao S, Zhang H, Liang J, Zhao C, Wang H, Hua B, Sun L. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017 Aug;17(3):333-340. doi: 10.1007/s10238-016-0427-0. Epub 2016 Jun 7. PMID: 27270729.
[6]Yingqian Zhu, Ce Huang, Liang Zheng et al. Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: a phase I/II randomized, double-blind, placebo-controlled study, 19 January 2024, PREPRINT (Version 1) available at Research Square [https://doi.org/10.21203/rs.3.rs-3847704/v1]